A randomized, double-blind, placebo-controlled study of oral almotriptan 6.25 mg, 12.5 mg, and 25 mg in the acute treatment of migraine in adolescents

被引：0

|

作者：

Linder, S. L.

Mathew, N. T.

Cady, R. K.

Finlayson, G.

Ishkanian, G.

Lewis, D. W.

Cabarrocas, X.

机构：

来源：

ANNALS OF NEUROLOGY | 2006年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：S152 / S152

页数：1

相关论文

共 50 条

[1] Almotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study
Allais, Gianni
Bussone, Gennaro
D'Andrea, Giovanni
Moschiano, Franca
d'Onofrio, Florindo
Valguarnera, Fabio
Manzoni, Gian Camillo
Grazzi, Licia
Allais, Rita
Benedetto, Chiara
Acuto, Giancarlo
[J]. CEPHALALGIA, 2011, 31 (02) : 144 - 151
[2] Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized, double-blind, placebo-controlled study
Winner, P
Lewis, D
Visser, WH
Jiang, KH
Ahrens, S
Evans, JK
[J]. HEADACHE, 2002, 42 (01): : 49 - 55
[3] Almotriptan for acute treatment of migraine: a randomized, double-blind, placebo-controlled study in Korea
Chung, C. S.
Park, K. Y.
Moon, H. S.
Joo, S. A.
Song, K. S.
Kim, J. A.
[J]. CEPHALALGIA, 2006, 26 (11) : 1392 - 1392
[4] Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg
Diener, HC
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (10) : 1603 - 1610
[5] Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study
Salonen, R
Ashford, EA
Hassani, H
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 1999, : 16 - 24
[6] The efficacy and tolerability of almotriptan 12.5 mg in acute migraine in patients who were poor responders to sumatriptan 50 mg: a randomized, placebo-controlled trial
Diener, HC
[J]. CEPHALALGIA, 2004, 24 (09) : 795 - 796
[7] A double-blind, randomized, parallel-group trial of almotriptan 12.5 mg vs placebo in migraine patients who respond poorly to sumatriptan 50 mg
Diener, HC
Gebert, I
[J]. NEUROLOGY, 2004, 62 (07) : A151 - A152
[8] Double-Blind, Placebo Controlled, Randomized Clinical Trial Comparing Melatonin 3 mg, Amitriptyline 25 mg and Placebo for Migraine Prevention
Peres, Mario
Goncalves, Andre
[J]. NEUROLOGY, 2013, 80
[9] Double-Blind, Placebo Controlled, Randomized Clinical Trial Comparing Melatonin 3 mg, Amitriptyline 25 mg and Placebo for Migraine Prevention
Peres, M. F. P.
Goncalves, A. L.
Ribeiro, R. T.
[J]. CEPHALALGIA, 2013, 33 (S8) : 94 - 95
[10] Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study
Lipton, Richard B.
Munjal, Sagar
Brand-Schieber, Elimor
Tepper, Stewart J.
Dodick, David W.
[J]. HEADACHE, 2020, 60 (01): : 58 - 70

← 1 2 3 4 5 →